Mitochondrial Dysfunction in Huntington’s Disease; Interplay Between HSF1, p53 and PGC-1α Transcription Factors

Taylor A. Intihar¹, Elisa A. Martinez² and Rocio Gomez-Pastor¹*

¹Department of Neuroscience, School of Medicine, University of Minnesota, Minneapolis, MN, United States, ²Department of Biochemistry and Molecular Biology, Dickinson College, Carlisle, PA, United States

Huntington’s disease (HD) is a neurodegenerative disease caused by an expanded CAG repeat in the huntingtin (HTT) gene, causing the protein to misfold and aggregate. HD progression is characterized by motor impairment and cognitive decline associated with the preferential loss of striatal medium spiny neurons (MSNs). The mechanisms that determine increased susceptibility of MSNs to mutant HTT (mHTT) are not fully understood, although there is abundant evidence demonstrating the importance of mHTT mediated mitochondrial dysfunction in MSNs death. Two main transcription factors, p53 and peroxisome proliferator co-activator PGC-1α, have been widely studied in HD for their roles in regulating mitochondrial function and apoptosis. The action of these two proteins seems to be interconnected. However, it is still open to discussion whether p53 and PGC-1α dependent responses directly influence each other or if they are connected via a third mechanism. Recently, the stress responsive transcription factor HSF1, known for its role in protein homeostasis, has been implicated in mitochondrial function and in the regulation of PGC-1α and p53 levels in different contexts. Based on previous reports and our own research, we discuss in this review the potential role of HSF1 in mediating mitochondrial dysfunction in HD and propose a unifying mechanism that integrates the responses mediated by p53 and PGC-1α in HD via HSF1.

Keywords: heat shock factor 1 (HSF1), mitochondrial dysfunction, Huntington (disease), p53, PGC-1α

INTRODUCTION

Mitochondria are critical organelles that control energy production, lipid metabolism, and Ca²⁺ signaling and buffering. Decreased mitochondrial function has been implicated in multiple cellular processes, linking dysfunctional mitochondria to a wide range of human diseases, including metabolic, cardiovascular, and neurological disorders (Ballinger, 2005; Lin and Beal, 2006; Bhatti et al., 2017). The specific role of mitochondrial dysfunction in the context of Huntington’s disease (HD) has been the subject of numerous reviews in recent years (Quintanilla and Johnson, 2009; Reddy et al., 2009; Jin and Johnson, 2010; Oliveira, 2010; Costa and Scorrano, 2012; Dubinsky, 2017). Now, new findings have provided evidence for a novel role of Heat Shock transcription Factor 1 (HSF1) in directly regulating both mitochondrial function and HD pathology. Therefore, we discuss in this article the molecular mechanisms that contribute to mitochondrial dysfunction.
in HD and speculate on the possible role of HSF1 in mediating this defect.

HD is an inherited neurodegenerative disease caused by a CAG triplet (encoding glutamine) repeat expansion in the huntingtin (HTT) gene that causes HTT protein to misfold and aggregate (MacDonald, 1993; DiFiglia et al., 1997). HD is manifested by progressive behavioral and motor impairment accompanied by cognitive decline. In HD, striatal GABAergic medium spiny neurons (MSNs) are particularly vulnerable. Progressive dysregulation of MSNs is strongly correlated with motor symptoms onset and severity (Ferrante et al., 1991).

Altered mitochondrial morphology is a hallmark of HD and different abnormalities can be seen in different cell types. In peripheral tissues (lymphoblast, myoblast and fibroblasts) mitochondria present an enlarged morphology, while neurons are characterized by increased mitochondrial fragmentation (Panov et al., 2002; Squitieri et al., 2006, 2010; Kim et al., 2010; Jin et al., 2013). Altered mitochondrial structure correlates with mitochondrial dysfunction in all HD cells which is manifested by decreased electron transport chain activity, oxygen consumption, Ca\(^{2+}\) buffering and decreased ATP and NAD\(^+\) production (Oliveira, 2010). It has been proposed that mutant HTT (mHTT)-mediated mitochondrial abnormalities significantly affect MSNs due to the high-energy demand of this neuronal subtype (Ferrante et al., 1991; Pickrell et al., 2011). This is one hypothesis that explains the increased vulnerability of MSNs in HD (Ferrante et al., 1991; Mitchell and Griffiths, 2003). In support of this hypothesis, mitochondria isolated from the striatum of adult rats showed higher sensitivity to Ca\(^{2+}\) induced membrane permeabilization than mitochondria from the cerebral cortex, suggesting that striatal neurons are selectively vulnerable to metabolic stress (Brustovetsky et al., 2003). Other factors that contribute to this cell-selective neurodepathy include; cell-type specific processing or localization of mHTT (Li et al., 2000; Menalled et al., 2002), abnormal interactions between mHTT and brain region specific protein partners and tissue specific differences in CAG instability (Kennedy et al., 2003; Goula et al., 2012). All these processes play important roles in promoting MSN degeneration, and although they could also contribute to increase mitochondrial stress, they are not the subject of this review.

HD patients and mouse models of HD exhibit well-described metabolic defects (Mochel and Haller, 2011; Mochel et al., 2012; Dubinsky, 2017). Metabolic analysis in presymptomatic patients with positron emission tomography (PET) and proton nuclear magnetic resonance (1H-NMR) showed that striatal glucose uptake and pyruvate utilization were reduced years before the onset of the motor symptoms, suggesting that mitochondrial alteration may be an early cause of disease progression (Antonini et al., 1996; Feigin et al., 2001). Other studies conducted in HD mouse models showed that MSN dendritic alterations appear even before mitochondrial respiratory defects can be observed, thus suggesting that energy deficits are a consequence of neuropathological changes (Guidetti et al., 2001). It is agreed that, either as a cause or as consequence, mitochondrial dysfunction is a key player in HD pathogenesis and progression. In recent years there has been a tremendous effort in developing therapeutic strategies towards improving mitochondrial function such as those aimed to stabilize mitochondria by boosting the production of ATP, decreasing membrane permeability and/or preventing oxidative damage (Reddy and Reddy, 2011; Corona and Duchen, 2016).

One additional function of mitochondria is to act as a reservoir for pro-apoptotic factors and therefore regulating cell death (Suzuki et al., 1999; Dumollard et al., 2009). Mitochondrial dysfunction, Ca\(^{2+}\) overload, and accumulation of reactive oxygen species (ROS) causes the mitochondrial permeability transition pore (mPTP) to open. mPTP opening triggers the intrinsic apoptotic pathway associated with the mitochondrial outer membrane permeabilization, cytochrome c release, and activation of caspase-3 (Choo et al., 2004; Quintanilla et al., 2017). The dysregulation of two main transcription factors p53 and PGC-1\(\alpha\) has been extensively studied in HD for their roles in mediating mitochondrial dysfunction, apoptosis, and neurodegeneration (reviewed by Oliveira, 2010). We will briefly review these mechanisms of action and their crosstalk and discuss the potential role of HSF1 as a converging mechanism that integrates the responses mediated by p53 and PGC-1\(\alpha\).

**ROLE OF p53 AND PGC-1\(\alpha\) IN MITOCHONDRIAL DYSFUNCTION**

Transcriptional dysregulation and mitochondrial dysfunction are interconnected processes in HD governed by the crosstalk between p53 and the mitochondrial biogenesis factor PGC-1\(\alpha\) (peroxisome proliferator-activated receptor \(\gamma\) co-activator 1\(\alpha\); Steffan et al., 2000; Jin and Johnson, 2010).

p53 is a transcription factor known for its role as a tumor suppressor through the regulation of several target genes with diverse biological functions including cell cycle arrest, DNA repair, metabolism, and apoptosis. p53 protein levels and activity are induced in the brain of HD patients and in cell and mouse models of HD\(^{33}\), explaining at least in part, the low tumor incidence observed in HD patients (Sørensen et al., 1999; Bae et al., 2005). mHTT strongly interacts with p53, and it has been proposed that such interaction impairs the recruitment of the E3 ligase Mdm2, thus increasing p53 stabilization (Steffan et al., 2000; Bae et al., 2005). Up-regulation of p53 leads to induced expression of different mitochondria associated proteins (e.g., Bax and Puma, linked to mitochondrial depolarization) and activation of apoptosis (Chipuk et al., 2004; La Spada and Morrison, 2005). The role of p53 in mediating mitochondrial dysfunction in HD was confirmed when primary neurons expressing mHTT were treated with the p53 inhibitor pifithrin-\(\alpha\) and showed improved mitochondrial membrane potential (MMP) and increased cell viability (Bae et al., 2005). Recently, p53 was shown to also participate in mediating mitochondrial related necrosis and fragmentation in HD via direct interaction with mitochondrial fission protein Drp1 (dynamin related protein; Guo et al., 2013, 2014). However, the molecular mechanism by which p53 inhibition exerts neuroprotection is still poorly understood.
PGC-1α represents another major player in the link between mHTT, transcriptional dysregulation, and mitochondrial dysfunction (Johri et al., 2013). PGC-1α is a transcriptional coactivator that governs the expression of nuclear-encoded mitochondrial genes and regulates several metabolic processes, including mitochondrial biogenesis and oxidative phosphorylation (Wu et al., 1999; Puigserver and Spiegelman, 2003). Strikingly, PGC-1α null mice manifest HD-like features including, striatal neuronal loss, hypothermia and motor alterations (Weydt et al., 2006; Lucas et al., 2012). The expression of PGC-1α is significantly downregulated in MSNs compared to other striatal cells in HD patients and transgenic mouse models (Cui et al., 2006; Weydt et al., 2006). PGC-1α expression impairment in HD is due, at least in part, to the interference of mHTT with the CREB/TAF4 signaling pathway (Cui et al., 2006), which is considered the major regulator of PGC-1α expression (Herzig et al., 2001). However, chromatin immunoprecipitation analysis conducted in murine striatal-like cells derived from WT (STHdhQ27) and HD (STHdhQ111) mice did not show differences in CREB/TAF4 binding to the PGC-1α promoter between the two cell types (Cui et al., 2006) suggesting that additional mechanisms may be involved in PGC-1α expression impairment (discussed elsewhere in this review).

Down-regulation of PGC-1α in HD is accompanied by decreased expression of several PGC-1α–dependent targets and MSN markers (Weydt et al., 2006; Lucas et al., 2012). Studies aimed to induce the expression of PGC-1α in transgenic models of HD showed that PGC-1α promoted not only mitochondrial biogenesis but also provided neuroprotective effects by activating autophagy and increasing the turnover of mHTT aggregates (Tsunemi et al., 2012). These studies demonstrated the important role of PGC-1α in HD, and have motivated the generation of several pharmacological activators due to its therapeutic potential (reviewed by Johri et al., 2013).

However, recent transcriptomic analyses comparing different HD mouse models with either PGC-1α null mice or mice lacking PGC-1α in MSNs revealed many differences between their transcriptional profiles, particularly in mitochondrial-related genes (Lucas et al., 2012; McMeekin et al., 2018). Unexpectedly, HD knock-in mice showed up-regulation of several PGC-1α-dependent genes in an age-dependent manner. These data suggest that further studies in other mouse models will be necessary to clarify the exact role of PGC-1α in regulating mitochondrial gene dysregulation in HD.

Different reports have suggested that p53 and PGC-1α may operate together in controlling mitochondrial function, although the relationship between these two transcription factors differs depending on the physiological context. Studies in transgenic mice overexpressing the mitochondrial monooamine oxidase-A (MAO-A), an enzyme related to cardiomyopathies, showed that transgenic hearts exhibited p53 accumulation and downregulation of PGC-1α (Villeneuve et al., 2013), similar to what is observed in HD neurons. However, additional studies conducted in SH-SYSY neuroblastoma cells upon glutathione shortage, showed that p53 binds to the PGC-1α promoter and positively regulates its expression (Aquilano et al., 2013), while in liver carcinoma cells Hep2G, p53, and PGC-1α proteins interact with each other and modulate their transactivation functions (Sen et al., 2011). These studies highlight the complexity in the regulatory mechanisms of these two transcription factors and open up the possibility to alternative regulatory pathways not yet described.

**HSF1 AS A PHYSIOLOGICAL REGULATOR OF MITOCHONDRIAL ACTIVITY**

HSF1 is well known as the major transcriptional regulator of the heat shock response (Anckar and Sistonen, 2011). However, in the last decade a rising number of studies have proposed HSF1 to be a multifaceted factor involved in the regulation of many different cellular processes including but not limited to cell proliferation, inflammation, synapse formation, and energy metabolism (reviewed by Gomez-Pastor et al., 2017b). Here, we will discuss recent studies that have placed HSF1 in the spotlight for its role in mitochondrial function and neurodegeneration.

Benjamin and colleagues Yan et al. (2002) were the first to report a major role of HSF1 in regulating mitochondrial activity by studying the heart of Hsf1−/− mice. Their studies showed that lack of HSF1 results in increased mPTP and increased ROS production. Additional studies in Hsf1−/− oocytes confirmed the role of HSF1 in maintaining mitochondrial function and integrity by exhibiting mitochondrial ultrastructural abnormalities, functional defects, and activation of the apoptotic protein caspase-3 (Bierkamp et al., 2010). More recently, studies in Hsf1−/− hepatocytes also revealed decreased ATP and NAD+ production and mitochondrial abnormalities attributed to altered Drp1 function (Qiao et al., 2017). However, whether these mitochondrial alterations were directly regulated by HSF1 or indirectly as a result of chaperone down-regulation is somewhat unclear.

Very elegantly, Nakai and colleagues Tan et al. (2015) showed that in primary mouse embryonic fibroblasts (MEFs) exposed to proteotoxic stress conditions, HSF1 recruits the mitochondrial SSBP1 factor (involved in replication of mitochondrial DNA) to the nucleus where they both co-operate to control the expression of several cytoplasmic/mitochondrial genes. Further studies in cancer cells also revealed that HSF1 directly regulates the expression of SMAC (mitochondria-derived activator of caspase) and other mitochondrial genes inhibiting mitochondrial apoptosis (Liang et al., 2015). These studies propose HSF1 as a novel mitochondrial responsive transcription factor (Lee et al., 2015).

Lack of HSF1 has also been associated with reduced neurogenesis, neuronal demyelination, and severe astrogliosis, leading to motor and cognitive deficits in aged mice (Santos and Saraiva, 2004; Homma et al., 2007; Uchida et al., 2011). Viability studies conducted in primary cortical astrocytes and neurons isolated from Hsf1−/− mice exposed to different oxidative stress conditions revealed that both cell types were more sensitive than cells isolated from WT mice. Protein oxidation is also greater in Hsf1−/− primary cultures (Homma et al., 2007). These results suggest that mitochondrial function could be impaired...
in different cell types in the brain of Hsf1<sup>−/−</sup> mice, although no reports have addressed this issue yet. Whether the neuronal effects observed in HSF1 null mice are caused by mere chaperone depletion or directly related to HSF1-dependent regulation of mitochondrial gene transcription remains uncertain.

Recent studies conducted in adipose tissue revealed that HSF1 directly activates PGC-1α transcription by binding to a non-canonical Heat Shock Element (HSE) identified in its promoter sequence (Ma et al., 2015). This study highlighted the potential role of HSF1 in directly regulating mitochondrial function via regulation of PGC-1α. It is known that adipose tissue from HSF1 null-mice display mitochondrial gene expression deficits (Ma et al., 2015). However, lack of transcriptional studies in those cells impedes to determine whether lack of HSF1 specifically affects PGC-1α-dependent gene expression. In order to answer that question, further studies comparing the transcriptional profiles of HSF1 null mice and PGC-1 null mice will be necessary.

On the other hand, HSF1 and PGC-1α proteins interact and co-localize on several HSF1 target promoters co-operating in the regulation of different genes under hyperthermia (Xu et al., 2016). In fact, PGC-1α null cells showed down-regulation of several heat shock proteins, similar to those observed in HSF1-null mice (Trinklein et al., 2004; Xu et al., 2016). Intriguingly, PGC-1α also acts as a repressor of HSF1-mediated transcriptional program in hepatocytes and in cancer (Minsky and Roeder, 2015). Therefore, despite the evidence demonstrating the crosstalk between HSF1 and PGC-1α, the regulatory mechanisms that control PGC-1α and HSF1 interactions in different cell types or disease conditions is unclear.

**HSF1 ROLE IN MEDIATING MITOCHONDRIAL DYSFUNCTION IN HD**

HSF1 plays a fundamental role in HD pathogenesis (recently reviewed by Gomez-Pastor et al., 2017b). Studies where HSF1 null mice were crossbred with the R6/2 mice revealed that lack of HSF1 worsens neurodegeneration and disease progression (Hayashida et al., 2010) while HD transgenic mice overexpressing a constitutive active form of HSF1 significantly ameliorated HD symptoms (Fujimoto et al., 2005). The levels of HSF1 and its activity are strongly depleted in the striatum of patients with HD and in cell and mouse models of HD (Hay et al., 2004; Labbadia et al., 2011; Chafekar and Duenwald, 2012; Riva et al., 2012; Maheshwari et al., 2014; Gomez-Pastor et al., 2017a). HSF1 depletion is caused by inappropriate up-regulation of MSNs in two proteins, the Protein Kinase CK2α’ and E3 ligase Fbxw7, that phosphorylate and ubiquitylate HSF1, respectively, signaling the protein for proteosomal degradation (Gomez-Pastor et al., 2017a). It is believed that decreased levels and activity of HSF1 contribute to neuronal dysfunction and
Intihar et al. HSF1 and Mitochondrial Dysfunction in Huntington’s Disease

**FIGURE 2** | HSF1 binds to PGC-1α promoter and regulates its expression in Huntington’s disease (HD) cells. (A) Western blot analysis in STHdhQ7 cells treated with scramble (Scr.) or siRNA for 24 h. Cell lysates were prepared in lysis buffer (25 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% SDS) and a total of 25 µg protein was loaded. (B) Diagram of PGC-1α promoter containing the non-canonical Heat Shock Element (HSE; Ma et al., 2015). (C) HSF1 chromatin immunoprecipitation in STHdhQ7 and STHdhQ111 cells using 1 µg anti-HSF1 antibody (Bethyl Laboratories, A303-176A) and primers described by Ma et al. (2015; forward TTCATGGATGTGCTGGGTTA, reverse TTACAGATGGTTGCTTGCACT) for the PGC-1α promoter (Ma et al., 2015). Obtained values were normalized using % of input and fold enrichment over IgG (negative control) for each strain. Data was then expressed as fold change binding relative to STHdhQ7 cells. (D) qRT-PCR for PGC-1α expression (forward ATGTGTCGCCTTCTTGCTCT, reverse ATCTACTGCCTGGGGACCTT) performed 36 h after transfection with empty-pcDNA or HSF1-pcDNA overexpressing plasmid. At least three independent experiments were carried out for each analysis. Statistical analyses were performed using T-test, *p-value < 0.05. *p-value < 0.05 (compared to STHdhQ7-pcDNA), #p-value < 0.05 (compared to STHdhQ7-HSF1).

pathogenesis, suggesting HSF1 as a potential therapeutic target for HD intervention (Sittler et al., 2001; Neef et al., 2011). This hypothesis is supported by CK2α’ allele knock-out studies in the HD KIQ175 mouse model, which resulted in increased HSF1 levels and neuronal chaperone expression, rescued MSNs morphology and synapse formation, and ameliorated weight loss associated to HD (Gomez-Pastor et al., 2017a).

Due to previous studies linking HSF1 to mitochondrial function and PGC-1α expression (described above), it is reasonable to hypothesize that depletion of HSF1 could also contribute to the mitochondrial dysfunction and abnormalities reported in HD. Current research in our lab supports this hypothesis. We present here unpublished data evaluating the effects of silencing HSF1 in the MMP of murine striatal STHdhQ7 cells and how MMP alterations under these conditions mirror the deficits observed in scramble STHdhQ111 treated cells (Figure 1). The effect on MMP was determined using the JC-1 assay, a fluorescence dye that distinguishes between energized (JC-1 red) and depolarized (JC-1 green) mitochondria. We observed increased mitochondrial depolarization (determined by the ratio JC-1 red/JC-1 green signals) in STHdhQ111 compared to STHdhQ7 cells, as previously described (Ruan et al., 2004; Figure 1A). More importantly, silencing HSF1 in STHdhQ7 cells resulted in a strong mitochondrial depolarization compared to scramble, similar to the results obtained in untreated STHdhQ111 cells. Cell viability analyses using CyQUANT XTT assay (Thermo Fisher X12223) demonstrated that decreased MMP in STHdhQ7 cells treated with siHSF1 is not secondary to cell death since no significant changes were observed between scramble and siHSF1 conditions (Figure 1B). On the contrary, cell viability was reduced in STHdhQ111 compared to STHdhQ7 cells, as previously described using similar assays (Singer et al., 2017). This defect was exacerbated upon silencing HSF1. This data suggests that mitochondrial dysfunction contributes to exacerbating the HD phenotype although it is not sufficient to cause cell death.

Decreased MMP in STHdhQ7 cells treated with siHSF1 was accompanied by a decrease in the levels of PGC-1α (Figure 2A). We then conducted HSF1 chromatin immunoprecipitation analysis on the promoter of PGC-1α. We demonstrated that HSF1 binds to the non-canonical HSE present in the promoter of PGC-1α in both STHdhQ7 and STHdhQ111 cells (Figures 2B,C). However, HSF1 binding was reduced in STHdhQ111 cells (Figure 2C) correlating with the previously reported depletion
of HSF1 and the reduced expression of PGC-1α in those same cells (Cui et al., 2006; Chafekar and Duenwald, 2012; Gomez-Pastor et al., 2017a). In line with HSF1 playing a role in the regulation of PGC-1α, overexpression of HSF1 in STHdhQ111 cells rescued the expression of PGC-1α (Figure 2D). These results suggest that depletion of HSF1 protein levels in HD (Gomez-Pastor et al., 2017a) could be responsible, at least in part, for the expression impairment of PGC-1α. In support of this hypothesis, we have previously observed that increasing HSF1 levels in the striatum of HD mice elevated the expression of PGC-1α and its downstream targets such as the cytochrome c and the mitochondrial transcription factor TFAM (Gomez-Pastor et al., 2017a). All this data provides evidence for the role of HSF1 degradation in contributing to mitochondrial dysregulation in HD. However, further experiments in vivo will be necessary to establish the direct connection between HSF1 depletion, mitochondrial impairment and PGC-1α down-regulation in HD.

CROSSTALK BETWEEN HSF1 AND p53-PGC1α AXIS

Different reports have revealed HSF1 crosstalk with the p53 pathway by directly regulating p53 stabilization and nuclear translocation (Li et al., 2008; Jin et al., 2009; Logan et al., 2009; Oda et al., 2018; Figure 3). In human diploid fibroblasts, acute depletion of HSF1 induces cellular senescence independent of chaperone-mediated protein homeostasis but dependent on activation of the p53-p21 pathway. This is partly because of the increased expression of dehydrogenase/reductase 2 (DHRS2), a putative MDM2 inhibitor. MDM2 regulates p53 degradation and its inhibition contributes to increased p53 levels and activation of apoptosis (Oda et al., 2018). A different study also reported increased levels of p53 in Hsf1−/− MEFs (Jin et al., 2009). However, the authors proposed an alternative HSF1 dependent mechanism for the up-regulation of p53 levels. They showed that αβ-crystallin, an HSF1-gene target, is necessary...
to recruit the E3 ligase Fbx4 that ubiquitylates p53 and controls p53 degradation. In the absence of HSF1, reduced levels of α-crystallin results in the stabilization of p53.

On the other hand, p53 has been shown to directly regulate the expression of the human E3 ligase Fbxw7, by binding to regulatory elements contained within the Fbxw7 coding sequence (Kimura et al., 2003; Mao et al., 2004). Since Fbxw7 is involved in HSF1 ubiquitylation (Kourtis et al., 2015; Gomez-Pastor et al., 2017a) it is possible that increased p53 levels in HD participates in the degradation of HSF1 by up-regulating Fbxw7 during disease progression. If this hypothesis is correct, this would establish a vicious cycle where depletion of HSF1 contributes to the stabilization of p53 levels, which in turn potentiates HSF1 degradation (Figure 3).

As we previously discussed, p53 and PGC-1α pathways are also interconnected processes where the levels of one factor influences the levels and activity of the other (Sen et al., 2011; Aquilano et al., 2013; Villeneuve et al., 2013). Considering all the evidence that connects HSF1, p53, and PGC-1α, we speculate on the existence of a p53-HSF1-PGC-1α axis that integrates transcriptional dysregulation and mitochondrial dysfunction into one single pathway (Figure 3). However, it will be necessary to conduct further research to put together all the pieces of the puzzle and connect these three transcription factors in the context of HD.

FUTURE DIRECTIONS

Numerous studies now demonstrated the role of HSF1 in regulating mitochondrial dysfunction in different contexts including HD. However, many questions still remain unresolved. First, it would be necessary to uncover whether elevation of p53 is responsible for the degradation of HSF1 in HD and whether the neuroprotection exerted by p53 inhibition is indeed mediated via HSF1. On the other hand, the direct role of HSF1 in regulating the expression of PGC-1α in HD and the consequences of such regulation on mitochondrial dysfunction in neurons needs to be further validated in other systems. These studies will be critical to fully understand the causes and consequences of HSF1 degradation in HD and will help to develop more efficient therapeutic strategies for HD intervention.

DATA AVAILABILITY

All datasets generated for this study are included in the manuscript.

AUTHOR CONTRIBUTIONS

TI conducted experiments and contributed with writing, preparing literature and reviewing the manuscript. EM conducted experiments shown in Figure 1 and contributed with reviewing the manuscript. RG-P contributed to the writing of the manuscript, preparing literature and designed the experiments shown in the manuscript.

FUNDING

We thank the University of Minnesota Undergraduate Research Opportunities Program (UROP; TI) and the R25 NS083059 University of Minnesota Summer Research in Neuroscience (EM) for their support and funding sources.

ACKNOWLEDGMENTS

We thank Dahyun Yu and Nicole Zarate for the technical support.

REFERENCES

Anckar, J., and Sistonen, L. (2011). Regulation of HSF1 function in the heat stress response: implications in aging and disease. Annu. Rev. Biochem. 80, 1089–1115. doi: 10.1146/annurev-biochem-060809-095203

Antonini, A., Leenders, K. L., Spiegel, R., Meier, D., Vontobel, P., Weigel-Weber, M., et al. (1996). Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington’s disease. Brain 119, 2085–2095. doi: 10.1093/brain/119.6.2085

Aquilano, K., Baldelli, S., Pagliel, B., Cannata, S. M., Rotilio, G., and Ciriolo, M. R. (2013). p53 orchestrates the PGC-1α-mediated antioxidant response upon mild redox and metabolic imbalance. Antioxid. Redox Signal. 18, 386–399. doi: 10.1089/ars.2012.4615

Bae, B. I., Xu, H., Igarashi, S., Fujimuro, M., Agrawal, N., Taya, Y., et al. (2005). p53 mediates cellular dysfunction and behavioral abnormalities in Huntington’s disease. Neuron 47, 29–41. doi: 10.1016/j.neuron.2005.06.005

Ballinger, S. W. (2005). Mitochondrial dysfunction in cardiovascular disease. Free Radic. Biol. Med. 38, 1278–1295. doi: 10.1016/j.freeradbiomed.2005.02.014

Bhatti, J. S., Bhatti, G. K., and Reddy, H. (2017). Mitochondrial dysfunction and oxidative stress in metabolic disorders—A step towards mitochondria based therapeutic strategies. Biochim. Biophys. Acta Mol. Basis Dis. 1863, 1066–1077. doi: 10.1016/j.bbadis.2016.11.010

Bierkamp, C., Luxey, M., Metchat, A., Audouard, C., Dumollard, R., and Christians, E. (2010). Lack of maternal Heat Shock Factor 1 results in multiple cellular and developmental defects, including mitochondrial damage and altered redox homeostasis and leads to reduced survival of mammalian oocytes and embryos. Dev. Biol. 339, 358–353. doi: 10.1016/j.ydbio.2009.12.037

Brustovetsky, N., Brustovetsky, T., Purl, K. J., Capano, M., Crompton, M., and Dubinsky, J. M. (2003). Increased susceptibility of striatal mitochondria to calcium-induced permeability transition. J. Neurosci. 23, 4858–4867. doi: 10.1523/jneurosci.23-12-04858.2003

Chafekar, S. M., and Duennwald, M. L. (2012). Impaired heat shock response in cells expressing full-length polyglutamine-expanded huntingtin. PLoS One 7:e37929. doi: 10.1371/journal.pone.0037929

Chipuk, J. E., Kuwana, T., Boucher-Hayes, L., Droin, N. M., Newmeyer, D. D., Schuler, M., et al. (2004). Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303, 1010–1014. doi: 10.1126/science.1092734

Choo, Y. S., Johnson, G. V., MacDonald, M., Detloff, P. J., and Lesort, M. (2004). Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum. Mol. Genet. 13, 1407–1420. doi: 10.1093/hmg/ddh162

Corona, J. C., and Duchen, M. R. (2016). PPARγ as a therapeutic target to rescue mitochondrial function in neurological disease. Free Radic. Biol. Med. 100, 153–163. doi: 10.1016/j.freeradbiomed.2016.06.023

Costa, V., and Scorrano, L. (2012). Shaping the role of mitochondria in the pathogenesis of Huntington’s disease. EMBO J. 31, 1853–1864. doi: 10.1038/emboj.2012.65
Dubinsky, J. M. (2017). Towards an understanding of energy impairment in Huntington’s disease brain. J. Neurosci. Dis. 6, 267–302. doi: 10.3233/JHD-170264

Dumollard, R., Carroll, J., Duchen, M. R., Campbell, K., and Swann, K. (2009). Mitochondrial function and redox state in mammalian embryos. Semin. Cell Dev. Biol. 20, 346–353. doi: 10.1016/j.semcdb.2008.12.013

Feigin, A., Leenders, K. L., Moeller, J. R., Missimer, J., Kuenig, G., Spetsieris, P., Dumollard, R., Carroll, J., Duchen, M. R., Campbell, K., and Swann, K. (2009). Mitochondrial loss, dysfunction and altered dynamics in Huntington’s disease. An [116f]FDG PET study. J. Nucl. Med. 42, 1591–1595.

Ferrante, R. J., Kowall, N. W., and Richardson, E. P. (1991). Proliferative and degenerative changes in striatal spiny neurons in Huntington’s disease: a combined study using the section-Golgi method and calbindin D28k immunocytochemistry. J. Neurosci. 11, 3877–3887. doi: 10.1523/jneurosci.11-12-03877.1991

Fujimoto, M., Takaki, E., Hayashi, T., Kitaura, Y., Tanaka, Y., Inouye, S., et al. (2005). Active HSF1 significantly suppresses polyglutamine aggregate formation in cellular and mouse models. J. Biol. Chem. 280, 34908–34916. doi: 10.1074/jbc.m506288200

Gomez-Pastor, R., Burchiel, E. T., Neef, D. W., Jaeger, A. M., Cabiscol, E., McKinstry, S. U., et al. (2017a). Altered chromatin architecture underlies progressive impairment of the heat shock response in model mouse models. Hum. Mol. Genet. 26, 267–302. doi: 10.3233/JHD-170387.

Lee, J. H., Lee, Y. K., Lim, J. J., Byun, H. O., Park, I., Kim, G. H., et al. (2015). Mitochondrial respiratory dysfunction induces claudin-1 expression via reactive oxygen species-mediated heat shock factor 1 activation, leading to hepatoma cell invasiveness. J. Biol. Chem. 290, 21421–21431. doi: 10.1074/jbc.m115.654913

Li, Q., Feldman, R. A., Radhakrishnan, V. M., Carey, S., and Martinez, J. D. (2008). Hsf1 is required for the nuclear translocation of p53 tumor suppressor. Neoplasia 10, 1138–1145. doi: 10.1593/neo.080430

Li, H., Li, S. H., Johnston, H., Shelbourne, P. F., and Li, X. J. (2000). Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity. Nat. Genet. 25, 385–389. doi: 10.1038/78054

Li, X., Moskophidis, D., Hu, Y., Phillips, A., and Mivechi, N. F. (2009). Heat shock factor 1 deficiency via its downstream target gene αB-crystallin (Hspb5) impairs p53 degradation. J. Cell. Biochem. 107, 504–515. doi: 10.1002/jcb.21251

Jin, Y. N., Yu, Y. V., Gundemir, S., Jo, C., Cui, M., Tieu, K., et al. (2013). Impaired mitochondrial dynamics and Nrf2 signaling contribute to compromised responses to oxidative stress in striatal cells expressing full-length mutant huntingtin. PLoS One 8:e57932. doi: 10.1371/journal.pone.0057932

Johni, A., Chandra, A., and Flint Beal, M. (2013). PGC-1α, mitochondrial dysfunction and Huntington’s disease. Free Radic. Biol. Med. 62, 37–46. doi: 10.1016/j.freeradbiomed.2013.04.016

Kennedy, L., Evans, E., Chen, M. C., Craven, L., Detloff, P. J., Ennis, M., et al. (2003). Dramatic tissue-specific mutation length increases are an early molecular event in Huntington disease pathogenesis. Hum. Mol. Genet. 12, 3359–3367. doi: 10.1093/hmg/ddg352

Kim, J., Moody, J. P., Edgerly, C. K., Bordiuk, O. L., Cormier, K., Smith, E., et al. (2010). Mitochondrial loss, dysfunction and altered dynamics in Huntington’s disease. Hum. Mol. Genet. 19, 3919–3935. doi: 10.1093/hmg/ddq306

Kimura, T., Gotoh, M., Nakamura, Y., and Arakawa, H. (2003). hCDC4b, a regulator of cyclin E, as a direct transcriptional target of p53. Cancer Sci. 94, 431–436. doi: 10.1111/j.1349-7006.2003.tb01460.x

Kouris, N., Moubarak, R. S., Aranda-Orgilles, B., Lui, K., Aydin, I. T., Trimarchi, T., et al. (2015). FBXW7 modulates cellular stress response and metastatic potential through HSF1 post-translational modification. Nat. Cell Biol. 17, 322–332. doi: 10.1038/ncb3121

La Spada, A. R., and Morrison, R. S. (2005). The power of the dark side: Huntington’s disease protein and p53 form a deadly alliance. Neuron 47, 1–3. doi: 10.1016/j.neuron.2005.06.023

Labbadia, J., Cunliiffe, H., Weiss, A., Katsyuba, E., Sathasivam, K., Seredenina, T., et al. (2011). Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease. J. Clin. Invest. 121, 3306–3319. doi: 10.1172/jci57413

Lee, J. H., Lee, Y. K., Lim, J. J., Byun, H. O., Park, I., Kim, G. H., et al. (2015). Mitochondrial respiratory dysfunction induces claudin-1 expression via reactive oxygen species-mediated heat shock factor 1 activation, leading to hepatoma cell invasiveness. J. Biol. Chem. 290, 21421–21431. doi: 10.1074/jbc.m115.654913

Lin, M. T., and Beal, M. F. (2006). Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443, 787–795. doi: 10.1038/nature05292

Logan, I. R., McNeill, H. V., Cook, S., Lu, X., Meek, D. W., Fuller-Pace, F. V., et al. (2009). Heat shock factor-1 modulates p53 activity in the transcriptional response to DNA damage. Nucleic Acids Res. 37, 2962–2973. doi: 10.1093/nar/gkp180

Lucas, E. K., Dougherty, S. E., McMeekin, L. J., Trinh, A. T., Reid, C. S., and Wellman, P. S. (2010). Developmental alterations in motor coordination and muscle spindly neuron markers in mice lacking pgc-1α. J. Exp. Biol. 213, 4287–4287. doi: 10.1242/jeb.078054

Ma, X., Xu, L., Alberobello, A. T., Gavrilova, O., Bagattin, A., Skarulis, M., et al. (2015). Celastrol protects against obesity and metabolic dysfunction through activation of a HSF1-PGC1α transcriptional axis. Cell Metab. 22, 695–708. doi: 10.1016/j.cmet.2015.08.005

MacDonald, M. (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Hum. Mol. Genet. 2, 697–703. doi: 10.1093/hmg/2.5.697

McKinstry, S. U., et al. (2017a). Abnormal degradation of the neuronal stress-regulator of cyclin E, as a direct transcriptional target of p53. Cancer Sci. 94, 431–436. doi: 10.1111/j.1349-7006.2003.tb01460.x

Mecho, E. T., and Thiele, D. J. (2017b). Regulation of heat formation in cellular and mouse models. J. Biol. Chem. 290, 21421–21431. doi: 10.1074/jbc.m115.654913

Montgomery, J. S., and Gelfand, E. (2000). CREB regulates hepatic glucoseogenesis through the coactivator PGC-1α. Nature 413, 179–183. doi: 10.1038/sj.nature00931

N.C. de Souza, I., and Soares, E. R. (2013). The relationship between mitochondrial dysfunction and transcriptional dysregulation in Huntington disease. J. Bioenerg. Biomembr. 45, 199–205. doi: 10.1007/s10863-010-9286-7
Reddy, H., Mao, P., and Manczak, M. (2009). Mitochondrial structural and functional dynamics in Huntington’s disease. Brain Res. Rev. 61, 33–48. doi: 10.1016/j.brainres.2009.03.042

Reddy, H., and Reddy, T. F. (2011). Mitochonadria as a therapeutic target for aging and neurodegenerative diseases. Curr. Alzheimer Res. 8, 393–409. doi: 10.2174/156720511797545601

Riva, L., Koeva, M., Yildirim, F., Pirhaji, L., Dinesh, D., Mazor, T., et al. (2012). Poly-glutamyne expanded huntingtin dramatically alters the genome wide binding of HSF1. J. Huntington Dis. 1, 33–45. doi: 10.3233/JHD-2012-1 20020

Ruan, Q., Lesort, M., MacDonald, M. E., and Johnson, G. V. (2004). Striatal cells from mutant huntingtin knock-in mice are selectively vulnerable to mitochondrial complex II inhibitor-induced cell death through a non-apoptotic pathway. Hum. Mol. Genet. 13, 669–681. doi: 10.1093/hmg/ddh982

Santos, S. D., and Saravia, M. J. (2004). Enlarged ventricles, astrogliosis and neurodegeneration in heat shock factor 1 null mouse brain. Neuroscience 126, 657–663. doi: 10.1016/j.neuroscience.2004.03.023

Sen, N., Satija, Y. K., and Das, S. (2011). PGC-1α, a key modulator of p53, promotes cell survival upon metabolic stress. Mol. Cell 44, 621–634. doi: 10.1016/j.molcel. 2011.08.044

Singer, E., Walter, C., Weber, J. J., Krahl, A. C., Mau-Holzmann, U. A., Rischert, N., et al. (2017). Reduced cell size, chromosomal aberration and altered proliferation rates are characteristics and confounding factors in the STHdh cell model of Huntington disease. Sci. Rep. 7:16880. doi: 10.1038/s41598-017-17275-4

Sittler, A., Lura, R., Lueder, G., Priller, J., Lehrhach, H., Hayer-Hartl, M. K., et al. (2001). Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington’s disease. Hum. Mol. Genet. 10, 1307–1315. doi:10.1093/hmg/10.12.1307

Sorensen, S. A., Fenger, K., and Olsen, J. H. (1999). Significantly lower incidence of cancer among patients with Huntington disease: an apoptotic effect of an expanded polyglutamine tract? Cancer 86, 1342–1346. doi: 10.1002/1097-0424(19991001)86:7<1342:AID-CNCR33>3.0.CO;2-3

Squitteri, F., Canna, M., Sgarbi, G., Maglione, V., Falleni, A., Lenzi, P., et al. (2006). Severe ultrastructural mitochondrial changes in lymphoblasts homozygous for Huntington disease mutation. Mech. Ageing Dev. 127, 217–220. doi:10.1016/j.mad.2005.09.010

Squitteri, F., Falleni, A., Canna, M., Oropello, S., Fulcieri, F., Lenzi, P., et al. (2010). Abnormal morphology of peripheral cell tissues from patients with Huntington disease. J. Neural Transm. 117, 77–83. doi: 10.1007/s00702-009-0328-4

Stefan, J. S., Kazantsev, A., Spasic-Bozovic, O., Greenwald, M., Zhu, Y. Z., Gohler, H., et al. (2000). The Huntington’s disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl. Acad. Sci. USA 97, 6763–6768. doi: 10.1073/pnas.10010097

Suzuki, A., Tsutomi, Y., Yamamoto, N., Shibutani, T., and Akahane, K. (1999). Mitochondrial regulation of cell death: mitochondria are essential for procaspase–3–p21 complex formation to resist Fas-mediated cell death. Mol. Cell. Biol. 19, 3842–3847. doi: 10.1128/mcb.19.5.3842

Tan, K., Fujimoto, M., Takit, R., Takaki, E., Hayashida, N., and Nakai, A. (2015). Mitochondrial SSBF1 protects cells from proteotoxic stresses by potentiating stress-induced HSF1 transcriptional activity. Nat. Commun. 6:6580. doi: 10.1038/ncomms7650

Trinklein, N. D., Murray, I. L., Hartman, S., Botstein, D., and Myers, R. M. (2004). The role of heat shock transcription factor 1 in the genome-wide regulation of the mammalian heat shock response. Mol. Biol. Cell. 15, 1254–1261. doi: 10.1091/mbc.e03-10-0738

Tsunemi, T., Ash, T. D., Morrison, B. E., Soriano, K. R., Au, J., Roque, R. A., et al. (2012). PGC-1α rescues Huntington’s disease’s proteotoxicity by preventing oxidative stress and promoting TFEB function. Sci. Transl. Med. 4:142ra97. doi: 10.1126/scitranslmed.3003799

Uchida, S., Hara, K., Kobayashi, A., Fujimoto, M., Otsubo, K., Yamagata, H., et al. (2011). Impaired hippocampal spinogenesis and neurogenesis and altered affective behavior in mice lacking heat shock factor 1. Proc. Natl. Acad. Sci. U. S. A 108, 1681–1686. doi: 10.1073/pnas.101642108

Villemouve, C., Guibaud-Frugier, C., Sicard, P., Laire, O., Ordeno, C., Duparc, T., et al. (2013). p53- PGC-1α pathway mediates oxidative mitochondrial damage and cardiomyocyte necrosis induced by monoamine oxidase-A upregulation: role in chronic left ventricular dysfunction in mice. Antioxid. Redox Signal. 18, 5–18. doi:10.1089/ars.2011.4373

Weidt, P., Pineda, V. V., Torrence, A. E., Libby, R. T., Satterfield, T. F., Lazarowski, E. R., et al. (2006). Therapeutically and metabolic defects in Huntington’s disease transgenic mice implicated PGC-1α in Huntington’s disease neurodegeneration. Cell Metab. 4, 349–362. doi: 10.1016/j.cmet.2006.0104

Puigserver, P., and Spiegelman, B. M. (2003). Peroxisome proliferator-activated receptor coactivator 1α (PGC-1α): transcriptional coactivator and metabolic regulator. Endocr. Rev. 24, 78–90. doi: 10.1210/er.2002-0012

Qiao, A., Jin, X., Pang, J., Moskophidis, D., and Mivechi, N. F. (2017). The transcriptional regulator of the chaperone response HSF1 controls hepatic bioenergetics and protein homeostasis. J. Cell Biol. 216, 723–741. doi: 10.1083/jcb.201607091

Quintanilla, R. A., and Johnson, G. (2009). Role of mitochondrial dysfunction in the pathogenesis of Huntington’s disease. Brain Res. Rev. 60, 242–247. doi: 10.1016/j.brainresboul.2009.07.010

Quintanilla, R. A., Tapia, C., and Perez, M. J. (2017). Possible role of mitochondrial permeability transition pore in the pathogenesis of Huntington disease. Biochem. Biophys. Res. Commun. 483, 1078–1083. doi: 10.1016/j.bbrc.2016.09.054

Reddy, H., Mao, P., and Manczak, M. (2009). Mitochondrial structural and functional dynamics in Huntington’s disease. Brain Res. Rev. 61, 33–48. doi: 10.1016/j.brainres.2009.03.042

Reddy, H., and Reddy, T. F. (2011). Mitochonadria as a therapeutic target for aging and neurodegenerative diseases. Curr. Alzheimer Res. 8, 393–409. doi: 10.2174/156720511797545601

Riva, L., Koeva, M., Yildirim, F., Pirhaji, L., Dinesh, D., Mazor, T., et al. (2012).
Wu, Z., Puigserver, P., Andersson, U., Zhang, C., Adelmant, G., Mootha, V., et al. (1999). Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. *Cell* 98, 115–124. doi: 10.1016/s0092-8674(00)80611-x

Xu, L., Ma, X., Bagattin, A., and Mueller, E. (2016). The transcriptional coactivator PGC1α protects against hyperthermic stress via cooperation with the heat shock factor HSF1. *Cell Death Dis.* 7:e2102. doi: 10.1038/cddis.2016.22

Yan, L. J., Christians, E. S., Liu, L., Xiao, X., Sohal, R. S., and Benjamin, I. J. (2002). Mouse heat shock transcription factor 1 deficiency alters cardiac redox homeostasis and increases mitochondrial oxidative damage. *EMBO J.* 21, 5164–5172. doi: 10.1093/emboj/cdf528

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2019 Intihar, Martinez and Gomez-Pastor. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*